# Evaluation of Consistency of StaphVAX Manufacturing Lots

> **NCT00211991** · PHASE3 · COMPLETED · sponsor: **Nabi Biopharmaceuticals** · enrollment: 354 (—)

## Conditions studied

- Staphylococcal Infections

## Interventions

- **BIOLOGICAL:** S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate

## Key facts

- **NCT ID:** NCT00211991
- **Lead sponsor:** Nabi Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2005-07
- **Final completion:** 2005-07
- **Target enrollment:** 354 (—)
- **Last updated:** 2012-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00211991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00211991, "Evaluation of Consistency of StaphVAX Manufacturing Lots". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00211991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*